ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 58 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,540 | +289.6% | 2,000 | 0.0% | 0.00% | – |
| Q2 2023 | $652 | +65100.0% | 2,000 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $1 | 0.0% | 2,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1 | -100.0% | 2,000 | -33.3% | 0.00% | -50.0% |
| Q3 2022 | $2,000 | -33.3% | 3,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | -66.7% | 3,000 | 0.0% | 0.00% | -66.7% |
| Q1 2022 | $9,000 | 0.0% | 3,000 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $9,000 | -30.8% | 3,000 | 0.0% | 0.01% | -33.3% |
| Q3 2021 | $13,000 | -27.8% | 3,000 | +50.0% | 0.01% | -30.8% |
| Q4 2020 | $18,000 | 0.0% | 2,000 | 0.0% | 0.01% | -31.6% |
| Q1 2020 | $18,000 | +200.0% | 2,000 | +100.0% | 0.02% | +280.0% |
| Q4 2019 | $6,000 | -25.0% | 1,000 | 0.0% | 0.01% | -16.7% |
| Q3 2019 | $8,000 | -42.9% | 1,000 | 0.0% | 0.01% | -50.0% |
| Q2 2019 | $14,000 | +180.0% | 1,000 | 0.0% | 0.01% | +140.0% |
| Q1 2019 | $5,000 | +66.7% | 1,000 | 0.0% | 0.01% | +66.7% |
| Q4 2018 | $3,000 | -62.5% | 1,000 | 0.0% | 0.00% | -57.1% |
| Q3 2018 | $8,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |